Ivantis gets $27M boost for trials of microstent in eye patients

02/4/2013 | Healio

A round of Series B financing led by Ascension Health Ventures has brought in $27 million for Ivantis. The company will use the money to conduct four global clinical studies of its Hydrus microstent, a tiny device that assists in restoring a glaucoma patient's natural eye outflow pathway.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN